304 related articles for article (PubMed ID: 32880844)
1. Relapse rate following withdrawal of anti-TNF therapy in patients with inflammatory bowel disease: A real-life cohort from northern India.
Sahu P; Vuyyuru SK; Kante B; Agarwal A; Sharma R; Das P; Panwar R; Jain S; Bopanna S; Makharia G; Kedia S; Ahuja V
Indian J Gastroenterol; 2020 Aug; 39(4):388-397. PubMed ID: 32880844
[TBL] [Abstract][Full Text] [Related]
2. Evolution After Anti-TNF Discontinuation in Patients With Inflammatory Bowel Disease: A Multicenter Long-Term Follow-Up Study.
Casanova MJ; Chaparro M; García-Sánchez V; Nantes O; Leo E; Rojas-Feria M; Jauregui-Amezaga A; García-López S; Huguet JM; Arguelles-Arias F; Aicart M; Marín-Jiménez I; Gómez-García M; Muñoz F; Esteve M; Bujanda L; Cortés X; Tosca J; Pineda JR; Mañosa M; Llaó J; Guardiola J; Pérez-Martínez I; Muñoz C; González-Lama Y; Hinojosa J; Vázquez JM; Martinez-Montiel MP; Rodríguez GE; Pajares R; García-Sepulcre MF; Hernández-Martínez A; Pérez-Calle JL; Beltrán B; Busquets D; Ramos L; Bermejo F; Barrio J; Barreiro-de Acosta M; Roncedo O; Calvet X; Hervías D; Gomollón F; Domínguez-Antonaya M; Alcaín G; Sicilia B; Dueñas C; Gutiérrez A; Lorente-Poyatos R; Domínguez M; Khorrami S; Muñoz C; Taxonera C; Rodríguez-Pérez A; Ponferrada A; Van Domselaar M; Arias-Rivera ML; Merino O; Castro E; Marrero JM; Martín-Arranz M; Botella B; Fernández-Salazar L; Monfort D; Opio V; García-Herola A; Menacho M; Ramírez-de la Piscina P; Ceballos D; Almela P; Navarro-Llavat M; Robles-Alonso V; Vega-López AB; Moraleja I; Novella MT; Castaño-Milla C; Sánchez-Torres A; Benítez JM; Rodríguez C; Castro L; Garrido E; Domènech E; García-Planella E; Gisbert JP
Am J Gastroenterol; 2017 Jan; 112(1):120-131. PubMed ID: 27958281
[TBL] [Abstract][Full Text] [Related]
3. Persistence on Anti-Tumour Necrosis Factor Therapy in Older Patients with Inflammatory Bowel Disease Compared with Younger Patients: Data from the Sicilian Network for Inflammatory Bowel Diseases (SN-IBD).
Porcari S; Viola A; Orlando A; Privitera AC; Ferracane C; Cappello M; Vitello A; Siringo S; Inserra G; Magnano A; Mocciaro F; Di Mitri R; Belluardo N; Fidanza O; Garufi S; Magrì G; Bertolami C; Carroccio A; Macaluso FS; Renna S; Ventimiglia M; Alibrandi A; Cottone M; Fries W;
Drugs Aging; 2020 May; 37(5):383-392. PubMed ID: 32016824
[TBL] [Abstract][Full Text] [Related]
4. Complete Endoscopic Healing Is Associated With Lower Relapse Risk After Anti-TNF Withdrawal in Inflammatory Bowel Disease.
Mahmoud R; Savelkoul EHJ; Mares W; Goetgebuer R; Witteman BJM; de Koning DB; van Tuyl SAC; Minderhoud I; Lutgens MWMD; Akol-Simsek D; van Schaik FDM; Fidder HH; Jansen JM; van Boeckel PGA; Mahmmod N; Horjus-Talabur Horje CS; Römkens TEH; Colombel JF; Hoentjen F; Jharap B; Oldenburg B;
Clin Gastroenterol Hepatol; 2023 Mar; 21(3):750-760.e4. PubMed ID: 36055567
[TBL] [Abstract][Full Text] [Related]
5. Long-term Outcomes after the Discontinuation of Anti-Tumor Necrosis Factor-α Therapy in Patients with Inflammatory Bowel Disease under Clinical Remission: A Korean Association for the Study of Intestinal Disease Multicenter Study.
Song JH; Kang EA; Park SK; Hong SN; Kim YS; Bang KB; Kim KO; Lee HS; Kang SB; Shin SY; Song EM; Im JP; Choi CH;
Gut Liver; 2021 Sep; 15(5):752-762. PubMed ID: 33767028
[TBL] [Abstract][Full Text] [Related]
6. Outcome of elective withdrawal of anti-tumour necrosis factor-α therapy in patients with Crohn's disease in established remission.
Brooks AJ; Sebastian S; Cross SS; Robinson K; Warren L; Wright A; Marsh AM; Tsai H; Majeed F; McAlindon ME; Preston C; Hamlin PJ; Lobo AJ
J Crohns Colitis; 2017 Dec; 11(12):1456-1462. PubMed ID: 25311864
[TBL] [Abstract][Full Text] [Related]
7. Relapse rates and predictors for relapse in a real-life cohort of IBD patients after discontinuation of anti-TNF therapy.
Bots SJ; Kuin S; Ponsioen CY; Gecse KB; Duijvestein M; D'Haens GR; Löwenberg M
Scand J Gastroenterol; 2019 Mar; 54(3):281-288. PubMed ID: 30907185
[No Abstract] [Full Text] [Related]
8. Discontinuation of anti-tumor necrosis factor therapy in inflammatory bowel disease patients: a prospective observation.
Bortlik M; Duricova D; Machkova N; Hruba V; Lukas M; Mitrova K; Romanko I; Bina V; Malickova K; Kolar M; Lukas M
Scand J Gastroenterol; 2016; 51(2):196-202. PubMed ID: 26329773
[TBL] [Abstract][Full Text] [Related]
9. The Risk of Relapse after Anti-TNF Discontinuation in Inflammatory Bowel Disease: Systematic Review and Meta-Analysis.
Gisbert JP; Marín AC; Chaparro M
Am J Gastroenterol; 2016 May; 111(5):632-47. PubMed ID: 27002797
[TBL] [Abstract][Full Text] [Related]
10. Comparison of drug survival between infliximab and adalimumab in inflammatory bowel disease.
Gil-Candel M; Gascón-Cánovas JJ; Urbieta-Sanz E; Rentero-Redondo L; Onteniente-Candela M; Iniesta-Navalón C
Int J Clin Pharm; 2020 Apr; 42(2):500-507. PubMed ID: 32006141
[TBL] [Abstract][Full Text] [Related]
11. Long-term outcome of inflammatory bowel disease patients with deep remission after discontinuation of TNFα-blocking agents.
Molander P; Färkkilä M; Kemppainen H; Blomster T; Jussila A; Mustonen H; Sipponen T
Scand J Gastroenterol; 2017 Mar; 52(3):284-290. PubMed ID: 27806638
[TBL] [Abstract][Full Text] [Related]
12. Outcome of inflammatory bowel disease patients treated with TNF-α inhibitors: two-year follow-up.
Lehtola E; Haapamäki J; Färkkilä MA
Scand J Gastroenterol; 2016 Dec; 51(12):1476-1481. PubMed ID: 27686143
[TBL] [Abstract][Full Text] [Related]
13. Clinical outcome after anti-tumour necrosis factor therapy discontinuation in 1000 patients with inflammatory bowel disease: the EVODIS long-term study.
Casanova MJ; Chaparro M; Nantes Ó; Benítez JM; Rojas-Feria M; Castro-Poceiro J; Huguet JM; Martín-Cardona A; Aicart-Ramos M; Tosca J; Martín-Rodríguez MDM; González-Muñoza C; Mañosa M; Leo-Carnerero E; Lamuela-Calvo LJ; Pérez-Martínez I; Bujanda L; Hinojosa J; Pajares R; Argüelles-Arias F; Pérez-Calle JL; Rodríguez-González GE; Guardiola J; Barreiro-de Acosta M; Gisbert JP;
Aliment Pharmacol Ther; 2021 Jun; 53(12):1277-1288. PubMed ID: 33962482
[TBL] [Abstract][Full Text] [Related]
14. Effectiveness and safety of anti-TNF therapy for inflammatory bowel disease in liver transplant recipients for primary sclerosing cholangitis: A nationwide case series.
Altwegg R; Combes R; Laharie D; De Ledinghen V; Radenne S; Conti F; Chazouilleres O; Duvoux C; Dumortier J; Leroy V; Treton X; Durand F; Dharancy S; Nachury M; Goutorbe F; Lamblin G; Boivineau L; Peyrin-Biroulet L; Pageaux GP
Dig Liver Dis; 2018 Jul; 50(7):668-674. PubMed ID: 29655972
[TBL] [Abstract][Full Text] [Related]
15. Patterns of anti-TNF use and associated treatment outcomes in inflammatory bowel disease patients: results from an analysis of Dutch health insurance claims data.
Bots SJA; Hoekman DR; Benninga MA; Ponsioen CY; D'Haens GR; Löwenberg M
Neth J Med; 2017 Dec; 75(10):432-442. PubMed ID: 29256410
[TBL] [Abstract][Full Text] [Related]
16. [Long-term follow-up of inflammatory bowel disease patients receiving anti-tumor necrosis factor-alpha therapy].
Bacsur P; Skribanek S; Milassin Á; Farkas K; Bor R; Fábián A; Rutka M; Bálint A; Szántó KJ; Tóth T; Nagy F; Szepes Z; Boda K; Molnár T
Orv Hetil; 2020 Nov; 161(47):1989-1994. PubMed ID: 33226355
[TBL] [Abstract][Full Text] [Related]
17. Relapse after withdrawal from anti-TNF therapy for inflammatory bowel disease: an observational study, plus systematic review and meta-analysis.
Kennedy NA; Warner B; Johnston EL; Flanders L; Hendy P; Ding NS; Harris R; Fadra AS; Basquill C; Lamb CA; Cameron FL; Murray CD; Parkes M; Gooding I; Ahmad T; Gaya DR; Mann S; Lindsay JO; Gordon J; Satsangi J; Hart A; McCartney S; Irving P; ; Lees CW
Aliment Pharmacol Ther; 2016 Apr; 43(8):910-923. PubMed ID: 26892328
[TBL] [Abstract][Full Text] [Related]
18. Undetectable anti-TNF drug levels in patients with long-term remission predict successful drug withdrawal.
Ben-Horin S; Chowers Y; Ungar B; Kopylov U; Loebstein R; Weiss B; Eliakim R; Del Tedesco E; Paul S; Roblin X
Aliment Pharmacol Ther; 2015 Aug; 42(3):356-64. PubMed ID: 26032402
[TBL] [Abstract][Full Text] [Related]
19. Systematic Review of Effects of Withdrawal of Immunomodulators or Biologic Agents From Patients With Inflammatory Bowel Disease.
Torres J; Boyapati RK; Kennedy NA; Louis E; Colombel JF; Satsangi J
Gastroenterology; 2015 Dec; 149(7):1716-30. PubMed ID: 26381892
[TBL] [Abstract][Full Text] [Related]
20. Proactive Therapeutic Drug Monitoring of Adalimumab Is Associated With Better Long-term Outcomes Compared With Standard of Care in Patients With Inflammatory Bowel Disease.
Papamichael K; Juncadella A; Wong D; Rakowsky S; Sattler LA; Campbell JP; Vaughn BP; Cheifetz AS
J Crohns Colitis; 2019 Aug; 13(8):976-981. PubMed ID: 30689771
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
